Altimmune reports Q4 net loss $31.6M; positive pemvidutide body composition data; HepTcell discontinued

Altimmune, Inc.

Net loss $31.6M ($0.54/share) for Q4 2023, including $12.4M impairment for discontinued HepTcell program.
Cash $198.0M; body composition: 74.5% weight loss from fat, 25.5% from lean mass on pemvidutide.
MOMENTUM: 15.6% mean weight loss at 48 weeks on 2.4 mg pemvidutide; >30% achieved ≥20% weight loss.
IMPACT Phase 2b MASH trial enrollment ongoing; topline 24-week data expected Q1 2025.
HepTcell development stopped; overall response in Phase 2 insufficient to warrant further advancement.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its full year and fiscal quarter ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.